同侧乳腺肿瘤复发患者重复前哨淋巴结活检的预后影响
该研究基于SNARB研究数据,分析515例同侧乳腺肿瘤复发(IBTR)患者,评估重复前哨淋巴结活检(rSLNB)及其他因素对远处无复发生存的影响。
要点
- 原发治疗至复发间隔<2年、三阴性IBTR、复发后未行辅助化疗与较差远处无复发生存独立相关。
- rSLNB作为IBTR患者分期工具的临床价值尚不明确。
核心结论
- rSLNB结果不是远处复发的重要预后因素,其作为IBTR患者分期工具的价值似乎存疑。
研究设计与样本
- 数据来自SNARB(Sentinel Node and Recurrent Breast Cancer)研究,共纳入515例同侧乳腺肿瘤复发患者,采用Cox比例风险分析评估肿瘤、患者和治疗因素对远处无复发生存的影响。
临床怎么用
- 对于IBTR患者,rSLNB结果不宜作为远处复发风险分层的主要依据。
- 应关注原发治疗至复发间隔短、三阴性IBTR及复发后未行辅助化疗等高危因素以指导随访和治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ipsilateral breast tumour recurrence (IBTR) has an unfavourable prognosis, with a significant subsequent risk of distant recurrence. Repeat sentinel lymph node biopsy (rSLNB) has recently been demonstrated to be technically feasible and useful in tailoring adjuvant treatment plans in patients with IBTR. The prognostic impact of rSLNB in patients with IBTR remains unclear. This study analysed the risk of distant recurrence after IBTR, and evaluated the prognostic impact of rSLNB and other patient and tumour characteristics on distant recurrence-free survival. METHODS: Data were obtained from the SNARB (Sentinel Node and Recurrent Breast Cancer) study. Cox proportional hazards analyses were performed to assess the prognostic effect of tumour, patient and treatment factors on distant recurrence-free survival. RESULTS: Of the 515 included patients, 230 (44·7 per cent) had a tumour-negative rSLNB and 46 (8·9 per cent) a tumour-positive rSLNB. In 239 patients (46·4 per cent) the rSLNB procedure was unsuccessful. After a median follow-up of 5·1 years, 115 patients (22·3 per cent) had developed a recurrence. The overall 5-year distant recurrence-free survival rate was 84·2 (95 per cent c.i. 80·7 to 87·7) per cent. An interval of less than 2 years between primary breast cancer treatment and ipsilateral recurrence (P = 0·018), triple-negative IBTR (P = 0·045) and absence of adjuvant chemotherapy after IBTR (P = 0·010) were independently associated with poor distant recurrence-free survival. The association between the outcome of rSLNB and distant recurrence-free survival was not statistically significant (P = 0·682). CONCLUSION: The outcome of rSLNB is not an important prognostic factor for distant recurrence, and its value as a staging tool in patients with IBTR seems disputable.
引用
- Poodt IGM, Vugts G, Schipper RJ, et al. Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence. Br J Surg. 2019. PMID: 30908615. doi:10.1002/bjs.11097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。